Blueprint Medicines Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	201.02	103.42	203.09
Depreciation & Amortization	26.67	21.59	21.57
Other Amortization	0.08	-	-
Loss (Gain) From Sale of Assets	-1.11	-1.41	0.08
Loss (Gain) From Sale of Investments	-	1.09	-3.16
Stock-Based Compensation	-	-	10.58
Provision & Write-off of Bad Debts	0.24	-0.18	0.1
Other Operating Activities	-1.48	-6.56	34.3
Change in Accounts Receivable	-39.5	22.1	-7.45
Change in Inventory	-19.78	31.13	-33.65
Change in Accounts Payable	-4.92	-0.35	-3.53
Change in Other Net Operating Assets	-1.92	-17.2	-57
Operating Cash Flow	159.32	153.64	164.92
Operating Cash Flow Growth	3.69%	-6.84%	-
Capital Expenditures	-40.79	-45.95	-30.67
Sale of Property, Plant & Equipment	1.16	1.41	0.7
Sale (Purchase) of Intangibles	-0.53	-	-
Investment in Securities	-	29.56	-19.73
Other Investing Activities	14.75	0.22	-6.59
Investing Cash Flow	-25.4	-14.77	-56.29
Short-Term Debt Issued	90	115	120
Total Debt Issued	90	115	120
Short-Term Debt Repaid	-115	-100	-120
Long-Term Debt Repaid	-10.81	-15.38	-14.79
Total Debt Repaid	-125.81	-115.38	-134.79
Net Debt Issued (Repaid)	-35.81	-0.38	-14.79
Common Dividends Paid	-49.01	-29.41	-
Financing Cash Flow	-84.82	-29.79	-14.79
Net Cash Flow	49.1	109.09	93.84
Free Cash Flow	118.53	107.69	134.26
Free Cash Flow Growth	10.07%	-19.79%	-
Free Cash Flow Margin	23.65%	30.55%	26.53%
Free Cash Flow Per Share	10.37	9.29	11.63
Cash Interest Paid	1.28	1.55	1.5
Cash Income Tax Paid	50.19	41.31	19.14
Levered Free Cash Flow	64.47	85.08	-
Unlevered Free Cash Flow	65.25	86.05	-
Change in Working Capital	-66.12	35.68	-101.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.